Comparing Biogen (BIIB) & Catalyst Biosciences (CBIO)

Biogen (NASDAQ: BIIB) and Catalyst Biosciences (NASDAQ:CBIO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Volatility and Risk

Biogen has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.

Insider & Institutional Ownership

87.8% of Biogen shares are held by institutional investors. Comparatively, 31.5% of Catalyst Biosciences shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 5.0% of Catalyst Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Biogen and Catalyst Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biogen $11.45 billion 5.95 $3.70 billion $16.31 19.75
Catalyst Biosciences $400,000.00 75.43 -$16.94 million ($13.12) -0.53

Biogen has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Biogen and Catalyst Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 0 10 17 1 2.68
Catalyst Biosciences 0 0 2 0 3.00

Biogen currently has a consensus price target of $345.23, suggesting a potential upside of 7.16%. Catalyst Biosciences has a consensus price target of $10.50, suggesting a potential upside of 50.00%. Given Catalyst Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Biogen.

Profitability

This table compares Biogen and Catalyst Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 29.44% 38.51% 20.80%
Catalyst Biosciences -2,438.50% -91.67% -55.28%

Summary

Biogen beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

About Biogen

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply